Efficacy of Lapaquistat Acetate and Simvastatin in Subjects With Primary Dyslipidemia.

PHASE3CompletedINTERVENTIONAL
Enrollment

411

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2007

Conditions
Hypercholesterolemia
Interventions
DRUG

Lapaquistat acetate and simvastatin

Lapaquistat acetate 50 mg, tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.

DRUG

Lapaquistat acetate and simvastatin

Lapaquistat acetate 100 mg, tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.

DRUG

Simvastatin

Lapaquistat acetate placebo-matching tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.

Trial Locations (53)

Unknown

Benešov

Holice V Čechách

Kladno

Mladá Boleslav

Olomouc

Prague

Trutnov

Ústí nad Orlicí

Zlín

Pärnu

Tallinn

Tartu

Aura

Helsinki

Hyvinkää

Oulu

Tampere

Turku

Berlin

Bochum

Chemnitz

Dresden

Frankfurt

Görlitz

Leipzig

Nuremberg

Krakow

Lublin

Niemodlin

Skierniewice

Sroda Wlkp.

Starachowice

Swietokrzyski

Warsaw

Zakopane

Bloemfontein

Cape Town

Johannesburg

Pretoria

Randburg

Tongaat

Bath

Birmingham

Blackpool

Blantyre

Chippenham

Eastwood

Glasgow

Harrow

Hinckley

Newport Isle of Wight

Nottingham

Woolpit

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY